☰

Brian T. Kawasaki, Ph.D. - Publications

Affiliations: 
University of California, Los Angeles, Los Angeles, CA 
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, White J, Farrar WL. Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Molecular Cancer Therapeutics. 9: 461-70. PMID 20124455 DOI: 10.1158/1535-7163.Mct-09-0507  0.407
2009 Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. The Prostate. 69: 827-37. PMID 19204913 DOI: 10.1002/Pros.20931  0.447
2009 Hurt EM, Klarmann GJ, Kawasaki BT, Sharifi N, Farrar WL. Prostate cancer stem cells Stem Cells and Cancer. 137-165. DOI: 10.1007/978-0-387-89611-3_6  0.341
2008 Kawasaki BT, Hurt EM, Mistree T, Farrar WL. Targeting cancer stem cells with phytochemicals. Molecular Interventions. 8: 174-84. PMID 18829843 DOI: 10.1124/Mi.8.4.9  0.352
2008 Qin HR, Kim HJ, Kim JY, Hurt EM, Klarmann GJ, Kawasaki BT, Duhagon Serrat MA, Farrar WL. Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. Cancer Research. 68: 7736-41. PMID 18829527 DOI: 10.1158/0008-5472.Can-08-1125  0.408
2008 Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends in Immunology. 29: 464-8. PMID 18775673 DOI: 10.1016/J.It.2008.07.005  0.363
2008 Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. British Journal of Cancer. 98: 756-65. PMID 18268494 DOI: 10.1038/Sj.Bjc.6604242  0.389
2007 Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochemical and Biophysical Research Communications. 364: 778-82. PMID 17964286 DOI: 10.1016/J.Bbrc.2007.10.067  0.398
2007 Sharifi N, Hurt EM, Kawasaki BT, Farrar WL. TGFBR3 loss and consequences in prostate cancer. The Prostate. 67: 301-11. PMID 17192875 DOI: 10.1002/Pros.20526  0.4
2006 Sharifi N, Kawasaki BT, Hurt EM, Farrar WL. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biology & Therapy. 5: 901-6. PMID 16855379 DOI: 10.4161/Cbt.5.8.2949  0.408
2006 Kawasaki BT, Liao Y, Birnbaumer L. Role of Src in C3 transient receptor potential channel function and evidence for a heterogeneous makeup of receptor- and store-operated Ca2+ entry channels. Proceedings of the National Academy of Sciences of the United States of America. 103: 335-40. PMID 16407161 DOI: 10.1073/Pnas.0508030102  0.503
2005 Yildirim E, Kawasaki BT, Birnbaumer L. Molecular cloning of TRPC3a, an N-terminally extended, store-operated variant of the human C3 transient receptor potential channel. Proceedings of the National Academy of Sciences of the United States of America. 102: 3307-11. PMID 15728370 DOI: 10.1073/Pnas.0409908102  0.441
Show low-probability matches.